ArticleFrontiers in immunology2026
Alopecia areata patients are associated with increased risk of glaucoma: a multicenter, retrospective cohort study.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Alopecia areata (AA) is a T cell-mediated autoimmune disease characterized by systemic immune activation that may extend to ocular tissues. However, whether AA increases the long-term risk of glaucoma remains unclear. Methods: We conducted a multicenter retrospective cohort study using the TriNetX Global Collaborative Network, comprising over 144 million patients across 147 healthcare organizations. For cross-database validation, we additionally performed a parallel analysis in another dataset, the US collaborative network, restricting the population to patients from healthcare organizations in the United States. Adults (≥18 years) with at least two visit records and a diagnosis of AA between 2005 and 2023 were included and matched 1:1 with individuals undergoing general health examinations without an AA diagnosis. Exclusion criteria included prior glaucoma, malignancy, or death before the index date. Propensity score matching incorporated demographic, socioeconomic, and clinical factors, including hypertension, diabetes, conjunctivitis, and Sjögren syndrome. The primary endpoint was new-onset glaucoma, with additional assessment of subtypes. Stratified analyses were performed by age and sex, and sensitivity analyses applied alternative definitions, matching models, and washout periods. Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated. Results: The final matched cohort included 28,966 patients with AA and 28,966 controls. During a 15-year follow-up, AA was associated with a higher risk of glaucoma (HR = 1.89; 95% CI, 1.51-2.38), consistent across models and sensitivity analyses. The risk was elevated for primary glaucoma (HR = 1.99; 95% CI, 1.10-3.62) and glaucoma-suspect states. Stratified analyses revealed stronger associations in females (HR = 1.78; 95% CI, 1.36-2.33) and older adults (≥65 years; HR = 2.76; 95% CI, 1.95-3.89). For the cross-database validation, the association remained significant in the US collaborative network, with a hazard ratio of 2.11 (95% CI, 1.72-2.59). Conclusions: AA was associated with a higher long-term risk of glaucoma across the primary, sensitivity, and cross-database analyses. However, this observational study establishes an epidemiologic association only and does not demonstrate a direct biological or immune-mediated link. Further prospective studies incorporating detailed ophthalmic examinations, longitudinal intraocular pressure measurements, retinal imaging, and systemic or ocular immune biomarkers are needed to determine whether shared inflammatory pathways contribute to this association.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.